AR and neoplasm: In agreement, both PC‐9/AR/shRNA and HCC827/AR/shRNA tumors were significantly responsive to osimertinib, whereas their corresponding control tumors minimally responded to osimertinib as evaluated by measuring both tumor sizes (Figure 5D,E) and weights (Figure 5F).